152 related articles for article (PubMed ID: 16854083)
1. Toward stable N4-modified neurotensins for NTS1-receptor-targeted tumor imaging with 99mTc.
Nock BA; Nikolopoulou A; Reubi JC; Maes V; Conrath P; Tourwé D; Maina T
J Med Chem; 2006 Jul; 49(15):4767-76. PubMed ID: 16854083
[TBL] [Abstract][Full Text] [Related]
2. [99mTc]Demotensin 5 and 6 in the NTS1-R-targeted imaging of tumours: synthesis and preclinical results.
Maina T; Nikolopoulou A; Stathopoulou E; Galanis AS; Cordopatis P; Nock BA
Eur J Nucl Med Mol Imaging; 2007 Nov; 34(11):1804-14. PubMed ID: 17594090
[TBL] [Abstract][Full Text] [Related]
3. [99mTc]demotensin VI: biodistribution and initial clinical results in tumor patients of a pilot/phase I study.
Gabriel M; Decristoforo C; Wöll E; Eisterer W; Nock B; Maina T; Moncayo R; Virgolini I
Cancer Biother Radiopharm; 2011 Oct; 26(5):557-63. PubMed ID: 21883013
[TBL] [Abstract][Full Text] [Related]
4. Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors.
Achilefu S; Srinivasan A; Schmidt MA; Jimenez HN; Bugaj JE; Erion JL
J Med Chem; 2003 Jul; 46(15):3403-11. PubMed ID: 12852770
[TBL] [Abstract][Full Text] [Related]
5. Novel 99mTc-labeled neurotensin analogues with optimized biodistribution properties.
Maes V; Garcia-Garayoa E; Bläuenstein P; Tourwé D
J Med Chem; 2006 Mar; 49(5):1833-6. PubMed ID: 16509599
[TBL] [Abstract][Full Text] [Related]
6. Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer.
de Visser M; Janssen PJ; Srinivasan A; Reubi JC; Waser B; Erion JL; Schmidt MA; Krenning EP; de Jong M
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1134-9. PubMed ID: 12768332
[TBL] [Abstract][Full Text] [Related]
7. Radiolabeled neurotensin analog, 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients.
Buchegger F; Bonvin F; Kosinski M; Schaffland AO; Prior J; Reubi JC; Bläuenstein P; Tourwé D; García Garayoa E; Bischof Delaloye A
J Nucl Med; 2003 Oct; 44(10):1649-54. PubMed ID: 14530481
[TBL] [Abstract][Full Text] [Related]
8. Double-stabilized neurotensin analogues as potential radiopharmaceuticals for NTR-positive tumors.
García-Garayoa E; Maes V; Bläuenstein P; Blanc A; Hohn A; Tourwé D; Schubiger PA
Nucl Med Biol; 2006 May; 33(4):495-503. PubMed ID: 16720241
[TBL] [Abstract][Full Text] [Related]
9. Catabolism of neurotensins. Implications for the design of radiolabeling strategies of peptides.
Schubiger PA; Allemann-Tannahill L; Egli A; Schibli R; Alberto R; Carrel-Rémy N; Willmann M; Bläuenstein P; Tourwé D
Q J Nucl Med; 1999 Jun; 43(2):155-8. PubMed ID: 10429510
[TBL] [Abstract][Full Text] [Related]
10. Novel neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors.
Alshoukr F; Rosant C; Maes V; Abdelhak J; Raguin O; Burg S; Sarda L; Barbet J; Tourwé D; Pelaprat D; Gruaz-Guyon A
Bioconjug Chem; 2009 Aug; 20(8):1602-10. PubMed ID: 19610615
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of a new, stabilized neurotensin(8--13) pseudopeptide radiolabeled with (99m)tc.
García-Garayoa E; Bläuenstein P; Bruehlmeier M; Blanc A; Iterbeke K; Conrath P; Tourwé D; Schubiger PA
J Nucl Med; 2002 Mar; 43(3):374-83. PubMed ID: 11884498
[TBL] [Abstract][Full Text] [Related]
12. Radionuclide imaging of small-cell lung cancer (SCLC) using 99mTc-labeled neurotensin peptide 8-13.
Zhang K; An R; Gao Z; Zhang Y; Aruva MR
Nucl Med Biol; 2006 May; 33(4):505-12. PubMed ID: 16720242
[TBL] [Abstract][Full Text] [Related]
13. Optimizing the Profile of [
Kanellopoulos P; Nock BA; Krenning EP; Maina T
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114537
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo evaluation of new radiolabeled neurotensin(8-13) analogues with high affinity for NT1 receptors.
García-Garayoa E; Allemann-Tannahill L; Bläuenstein P; Willmann M; Carrel-Rémy N; Tourwé D; Iterbeke K; Conrath P; Schubiger PA
Nucl Med Biol; 2001 Jan; 28(1):75-84. PubMed ID: 11182567
[TBL] [Abstract][Full Text] [Related]
15. New neurotensin analogue radiolabeled by 99m-technetium as a potential agent for tumor identification.
Emrarian I; Sadeghzadeh N; Abedi SM; Abediankenari S
Chem Biol Drug Des; 2018 Jan; 91(1):304-313. PubMed ID: 28816013
[TBL] [Abstract][Full Text] [Related]
16. 99mTc-HYNIC-Gastrin Peptides: Assisted Coordination of 99mTc by Amino Acid Side Chains Results in Improved Performance Both In Vitro and In Vivo.
King R; Surfraz MB; Finucane C; Biagini SC; Blower PJ; Mather SJ
J Nucl Med; 2009 Apr; 50(4):591-8. PubMed ID: 19289435
[TBL] [Abstract][Full Text] [Related]
17. CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs.
Nock BA; Maina T; Béhé M; Nikolopoulou A; Gotthardt M; Schmitt JS; Behr TM; Mäcke HR
J Nucl Med; 2005 Oct; 46(10):1727-36. PubMed ID: 16204724
[TBL] [Abstract][Full Text] [Related]
18. Stabilization of neurotensin analogues: effect on peptide catabolism, biodistribution and tumor binding.
Bruehlmeier M; Garayoa EG; Blanc A; Holzer B; Gergely S; Tourwé D; Schubiger PA; Bläuenstein P
Nucl Med Biol; 2002 Apr; 29(3):321-7. PubMed ID: 11929702
[TBL] [Abstract][Full Text] [Related]
19. Facile Preparation of a Thiol-Reactive (18)F-Labeling Agent and Synthesis of (18)F-DEG-VS-NT for PET Imaging of a Neurotensin Receptor-Positive Tumor.
Wu Z; Li L; Liu S; Yakushijin F; Yakushijin K; Horne D; Conti PS; Li Z; Kandeel F; Shively JE
J Nucl Med; 2014 Jul; 55(7):1178-84. PubMed ID: 24854793
[TBL] [Abstract][Full Text] [Related]
20. Organometallic 99mTc(III) '4 + 1' bombesin(7-14) conjugates: synthesis, radiolabeling, and in vitro/in vivo studies.
Kunstler JU; Veerendra B; Figueroa SD; Sieckman GL; Rold TL; Hoffman TJ; Smith CJ; Pietzsch HJ
Bioconjug Chem; 2007; 18(5):1651-61. PubMed ID: 17663527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
